Comparative Pharmacology
Head-to-head clinical analysis: LYRICA CR versus TIAGABINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYRICA CR versus TIAGABINE HYDROCHLORIDE.
LYRICA CR vs TIAGABINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and inhibiting excitatory neurotransmitter release (e.g., glutamate, norepinephrine, substance P).
Tiagabine inhibits GABA reuptake into presynaptic neurons and glial cells by binding to the GAT-1 GABA transporter, thereby increasing synaptic GABA concentrations and enhancing inhibitory neurotransmission.
Initial 75 mg orally twice daily (150 mg/day), or 50 mg three times daily (150 mg/day). Based on efficacy and tolerability, may increase to 150 mg twice daily (300 mg/day) after 1 week, then to 225 mg twice daily (450 mg/day) if needed. Maximum dose 450 mg/day. Take with food. Administer whole; do not split, crush, or chew.
Initial: 4 mg orally once daily; titrate by 4-8 mg/day at weekly intervals. Maintenance: 32-56 mg/day divided 2-4 times daily. Maximum dose: 56 mg/day.
None Documented
None Documented
6.3 hours (mean terminal elimination half-life); correlates with creatinine clearance, prolonged in renal impairment.
Terminal half-life of 5–8 hours in healthy adults; prolonged to 12–16 hours in hepatic impairment. Reduces with enzyme-inducing co-medications.
Primarily renal excretion as unchanged drug (98-99% of absorbed dose); <0.1% biliary/fecal.
Primarily hepatic metabolism via CYP3A4, with <2% excreted unchanged in urine. 63% of dose excreted in feces, 25% in urine as metabolites.
Category C
Category A/B
Anticonvulsant
Anticonvulsant